Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biora Therapeutics Inc

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biora Therapeutics excels in therapeutics programs, secures strategic partnerships

Biora Therapeutics demonstrated strong performance in key programs, maintained financial stability, and expressed confidence in future prospects.
While facing challenges in device performance and operational planning, the company is well-positioned to capitalize on opportunities for growth and innovation.
Overall, Biora's focus on advancing therapeutic programs and strategic collaborations signals a positive trajectory for the company's future success.

Biora Therapeutics reports stable finances, progresses key drug programs

Biora Therapeutics showcased solid financial management with increased operating expenses but a stable cash position, while also securing additional funding for growth.
The company's focus on key programs and strategic collaborations, coupled with the appointment of a new Chief Medical Officer, bodes well for its clinical development efforts.
Despite challenges in managing expenses and optimizing capital structure, Biora's promising results and strategic initiatives offer opportunities for future growth and success in the pharmaceutical industry.

Biora Therapeutics advances drug delivery platforms and maintains financial stability

Biora Therapeutics showcased progress on innovative drug delivery platforms in Q2 2023. The company's financials remain stable, with a focus on disciplined cash management. Securing partnerships and advancing regulatory filings are key focus areas for future growth.

Biora Therapeutics reduces debt, advances key platforms amid financial challenges

Biora Therapeutics demonstrated financial progress alongside operational advancements in its NaviCap and BioJet platforms, despite facing increased expenses and a net loss for the quarter.
The company's focus on FDA clearance for BT-600 trial initiation and collaborations for the BioJet platform highlights its commitment to advancing innovative therapies and partnerships.
While challenges persist in financial management and collaboration coordination, Biora Therapeutics remains poised to leverage opportunities for growth and market expansion in the biopharmaceutical sector.

Biora Therapeutics excels in Q4 2023 with innovative drug technologies

Biora Therapeutics made significant strides in Q4 2023, advancing their platform technologies and strengthening their financial position. While facing challenges in clinical trials and market competition, the company is well-positioned to capitalize on opportunities for growth and partnerships in the coming year.

Biora Therapeutics advances drug delivery platforms, strengthens financial position

Biora Therapeutics' Q1 performance reflects a strategic focus on R&D, financial strength, and advancements in targeted drug delivery platforms.
The company faces challenges in optimizing partnerships and capital structure while balancing innovation and financial sustainability.
Opportunities lie in upcoming data releases, clinical studies, and partnerships to drive growth and market expansion in 2024.

Biora Therapeutics excels in Q2 with breakthrough drug delivery platforms

Biora Therapeutics' innovative drug delivery platforms show promise in revolutionizing ulcerative colitis treatment and advancing JAK inhibitor therapy.
The company's successful Phase I trial results and capital raise provide a strong foundation for future growth and partnership opportunities.
While challenges lie ahead in scaling up and navigating the competitive landscape, Biora's focus on breakthrough technologies positions them well for success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Study demonstrated device functioned as designed when administered with food, potentially enabling non-fasted administration Study demonstrated device functioned as designed when administered with food, potentially enabling non-fasted administration

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform

SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of an abstract presenting data on the autonomous triggering and injection efficiency of its systemic therapeutics delivery system by the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference. This meeting explores the latest technological advances in the drug delivery devices arena and will take place in Palm Springs, California, October 18-19, 2022.

Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Oral Presentation Delivered at DDW 2022 Informs Clinical Study Design for Biora's Targeted Therapeutics Platform Oral Presentation Delivered at DDW 2022 Informs Clinical Study Design for Biora's Targeted Therapeutics Platform

Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis

Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis

Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022

Marks 29 Patents Worldwide Directed to Biora's Device Localization Technology Marks 29 Patents Worldwide Directed to Biora's Device Localization Technology

Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the Company's management team will be presenting a corporate overview and participating in one-on-one meetings, upon request, with conference attendees at the upcoming H.C. Wainwright Global Investment Conference, which is taking place both virtually and in-person at the Fontainebleau Hotel in Miami, Florida, May 23 to 26, 2022.

Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Chuck Padala – Managing Director, LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d'Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Sahil Kazmi – B. Riley Securities Operator Welcome to the Biora Therapeutics First Quarter 2022 Earnings Call.

Biora Therapeutics' (BIOR) CEO Adi Mohanty on Q1 2022 Results - Earnings Call Transcript

Completed transformation with the launch of Biora Therapeutics to reflect the company's focus on oral therapeutic solutions

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Biora's product is supposed to enable biologics to be delivered directly to GI tracts. BIOR stock is a favorite of retail investors.

BIOR Stock Starts Trading as Progenity's Rebrand Takes Shape. What to Know.

News for Biora Therapeutics Inc Stock (BIOR)